Finally, this study demonstrates that metastatic disease is not more frequent in MEN2 patients with high-risk RET mutations, i.e., mutations in codon C634, than in MEN2 patients with moderate-risk RET variants. The gene discussed is RET; the disease is metastatic neoplasm.